Developing a human-based stem cell model for reproductive toxicity
Developing a high-throughput human-based assay for male reproductive toxicity to enhance drug safety testing and reduce reliance on animal models.
Projectdetails
Introduction
Environmental factors and chemicals are thought to be one cause of declining male fertility. Reproductive toxicity is becoming a major public health problem. Currently, new pharmacological or chemical compounds are tested in animals for their effects on reproduction before entering the market. This risk assessment is essential but time-consuming, expensive, and is not always predictive in humans since animals have different reproductive characteristics and physiology. A validated and qualified human system to assess reproductive toxicity would be invaluable in addressing this conundrum between regulatory requirements and true relevance.
Project Overview
Through my ERC-CoG, I have built a large repository of knowledge and developed robust technology on human in vitro gametogenesis, more specifically on how to generate male gamete progenitors from human pluripotent stem cells. This, together with my bioinformatics know-how, makes me exceptionally well-placed to optimize a human-based high-throughput screening assay for male reproductive toxicity for use by the private sector in filing reproductive safety data to the regulatory authorities.
ReproTox Assay Development
This ReproTox assay will be further optimized by:
- Increasing throughput
- Standardizing measurements
Additionally, it will be integrated with a software innovation, including a machine learning algorithm to automate quantification and a web tool. Before we carry out a pilot screen using FDA-approved spermatotoxic compounds, we will conduct market research to define the commercialization route.
Expected Outcomes
Reducing the number of compounds that show male reproductive toxicity at very early stages of drug development will contribute to an effective first-tier toxicity screening. This will not only provide standard protocols for:
- Quantitative
- Rapid
- Cost-effective
- High-throughput
- Scalable
- Reproducible toxicity testing
But also reduce, and perhaps eventually replace, animal use. ReproTox will ultimately lead to economic, societal, environmental, health, and ethical benefits.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 150.000 |
Totale projectbegroting | € 150.000 |
Tijdlijn
Startdatum | 1-8-2024 |
Einddatum | 31-1-2026 |
Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- ACADEMISCH ZIEKENHUIS LEIDENpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
SAfeguarding female FERtility -development of human-relevant in vitro tools for reproductive toxicitySAFER aims to develop innovative, animal-free assays for assessing reproductive toxicity in women, using advanced technologies to identify harmful chemicals and promote safer environments. | ERC Consolid... | € 2.000.000 | 2024 | Details |
Representative, Reliable and Reproducible in vitro Models of the Human TestesThe project aims to develop a reliable preclinical model of human testes using tailored hydrogels to improve male infertility treatments through high-throughput experimentation and automated analysis. | ERC Starting... | € 1.499.980 | 2022 | Details |
Human blastoids: a drug discovery platform for women’s reproductive healthBLASTOID-DISCOVERY aims to utilize human blastoids as a scalable and ethical model for drug discovery to enhance women's reproductive health and reduce development costs. | ERC Proof of... | € 150.000 | 2023 | Details |
Towards Artificial Human Embryoid Models: Engineered and Synthetic Platforms for Ex Utero Mammalian EmbryogenesisDevelop biotechnological platforms to culture mammalian embryos ex utero and create synthetic embryoids for advancing stem cell research and disease modeling. | ERC Consolid... | € 2.000.000 | 2023 | Details |
Reprogramming of somatic cells into organOids: patient-centred neurodevelopmental disease modelling from nascent induced pluripotencyThe project aims to develop a robust method for generating human brain organoids from patients with Fragile X Syndrome to explore neurodevelopmental phenotypes and inform targeted therapies. | ERC Advanced... | € 2.500.000 | 2023 | Details |
SAfeguarding female FERtility -development of human-relevant in vitro tools for reproductive toxicity
SAFER aims to develop innovative, animal-free assays for assessing reproductive toxicity in women, using advanced technologies to identify harmful chemicals and promote safer environments.
Representative, Reliable and Reproducible in vitro Models of the Human Testes
The project aims to develop a reliable preclinical model of human testes using tailored hydrogels to improve male infertility treatments through high-throughput experimentation and automated analysis.
Human blastoids: a drug discovery platform for women’s reproductive health
BLASTOID-DISCOVERY aims to utilize human blastoids as a scalable and ethical model for drug discovery to enhance women's reproductive health and reduce development costs.
Towards Artificial Human Embryoid Models: Engineered and Synthetic Platforms for Ex Utero Mammalian Embryogenesis
Develop biotechnological platforms to culture mammalian embryos ex utero and create synthetic embryoids for advancing stem cell research and disease modeling.
Reprogramming of somatic cells into organOids: patient-centred neurodevelopmental disease modelling from nascent induced pluripotency
The project aims to develop a robust method for generating human brain organoids from patients with Fragile X Syndrome to explore neurodevelopmental phenotypes and inform targeted therapies.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Cultivating hope one star sperm at a timeSpermotile aims to revolutionize male infertility treatment by providing an automated, AI-driven sperm selection platform that enhances ART success rates and reduces costs for clinics and patients. | EIC Transition | € 2.499.906 | 2025 | Details |
Multi-organ toxicity and efficacy test platform for Personalized medicine & Drug developmentCherry Biotech aims to revolutionize drug development and personalized medicine by providing a patented 3D cell culture platform that enhances predictability and reduces reliance on animal testing. | EIC Accelerator | € 2.499.831 | 2024 | Details |
Engineering a living human Mini-heart and a swimming Bio-robotThe project aims to develop advanced in vitro human cardiac models, including a vascularized mini-heart and a bio-robot, to better assess cardiotoxicity and improve understanding of cardiovascular disease. | EIC Pathfinder | € 4.475.946 | 2022 | Details |
Bringing 3D cardiac tissues to high throughput for drug discovery screensDeveloping a high-throughput 3D cardiac model using microfluidic technology to enhance drug discovery for cardiovascular disease by improving predictive accuracy and scalability. | EIC Transition | € 1.457.500 | 2023 | Details |
Simultaneous Multiparametric MEA based platform for in-vitro chronic cardiotoxicity assessment with live-cell fluorescence imaging and electrophysiology.SiMulTox develops a novel platform for simultaneous long-term assessment of functional and structural cardiotoxicity, aiming to enhance drug safety evaluation and reshape the in-vitro testing market. | EIC Transition | € 786.875 | 2022 | Details |
Cultivating hope one star sperm at a time
Spermotile aims to revolutionize male infertility treatment by providing an automated, AI-driven sperm selection platform that enhances ART success rates and reduces costs for clinics and patients.
Multi-organ toxicity and efficacy test platform for Personalized medicine & Drug development
Cherry Biotech aims to revolutionize drug development and personalized medicine by providing a patented 3D cell culture platform that enhances predictability and reduces reliance on animal testing.
Engineering a living human Mini-heart and a swimming Bio-robot
The project aims to develop advanced in vitro human cardiac models, including a vascularized mini-heart and a bio-robot, to better assess cardiotoxicity and improve understanding of cardiovascular disease.
Bringing 3D cardiac tissues to high throughput for drug discovery screens
Developing a high-throughput 3D cardiac model using microfluidic technology to enhance drug discovery for cardiovascular disease by improving predictive accuracy and scalability.
Simultaneous Multiparametric MEA based platform for in-vitro chronic cardiotoxicity assessment with live-cell fluorescence imaging and electrophysiology.
SiMulTox develops a novel platform for simultaneous long-term assessment of functional and structural cardiotoxicity, aiming to enhance drug safety evaluation and reshape the in-vitro testing market.